Wenjiao Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Wenjiao Li has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Chuanlu Xu
Shanghai First Maternity and Infant Health Hospital, School of Medicine, Tongji University, Shanghai, 200040, China
1 shared publication- Gang Sun
School of Life Sciences, Fudan University, 220 Handan Road, Shanghai 200433, China
1 shared publication - Haichuan Li
Shanghai Changning Maternity and Infant Health Hospital, 773 Wuyi Road, Shanghai 200051, China
1 shared publication - Qun Shu
Department of Obstetrics, Shanghai First Maternity and Infant Health Hospital, School of Medicine, Tongji University, Shanghai, China
1 shared publication - Wang-Sheng Wang
Department of Reproductive Medicine, Shanghai Key Laboratory for Assisted Reproduction and Reproductive Genetics, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P.R. China
1 shared publication Zhenli Shan
Shanghai First Maternity and Infant Health Hospital, School of Medicine, Tongji University, Shanghai, 200040, China
1 shared publication
Latest Publications
- 1 August 2019
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 516 (2) , 402-407
Enhanced PDGF signaling in gestational diabetes mellitus is involved in pancreatic β-cell dysfunction
- 1 August 2019
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 516 (2) , 402-407
Enhanced PDGF signaling in gestational diabetes mellitus is involved in pancreatic β-cell dysfunction
- Open Access
- 9 April 2014
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 15 (4) , 6019-6030
Vasostatin Inhibits VEGF-Induced Endothelial Cell Proliferation, Tube Formation and Induces Cell Apoptosis under Oxygen Deprivation
Anti-angiogenesis treatment has been a promising new form of cancer therapy. Endothelial cells are critical for vascular homeostasis and play important roles in angiogenesis, vascular and tissue remodeling. Vasostatin, the 180 amino acid N-terminal fragment of the calreticulin protein, is reported to be a potent endogenous inhibitor of angiogenesis, suppressing tumor growth. However, the mechanism of these effects has not been sufficiently investigated. This study was performed to investigate the possible mechanism of vasostatin effects on primary cultured human umbilical vein endothelial cells (HUVEC). We found that vasostatin could inhibit the cell viability of HUVEC and induce cell apoptosis through mitochondrial pathways via activation of caspase-3 under oxygen deprivation conditions. Meanwhile, vasostatin also inhibited vascular endothelial growth factor-induced proliferation and tube formation of HUVEC. The possible mechanism of vasostatin-inhibited proliferation of HUVEC could be through down-regulation of endothelial nitric oxide synthase. These findings suggest that vasostatin could regulate endothelial cell function and might be used in anti-angiogenesis treatment.
- 9 April 2014
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 15 (4) , 6019-6030
Open AccessVasostatin Inhibits VEGF-Induced Endothelial Cell Proliferation, Tube Formation and Induces Cell Apoptosis under Oxygen Deprivation
Anti-angiogenesis treatment has been a promising new form of cancer therapy. Endothelial cells are critical for vascular homeostasis and play important roles in angiogenesis, vascular and tissue remodeling. Vasostatin, the 180 amino acid N-terminal fragment of the calreticulin protein, is reported to be a potent endogenous inhibitor of angiogenesis, suppressing tumor growth. However, the mechanism of these effects has not been sufficiently investigated. This study was performed to investigate the possible mechanism of vasostatin effects on primary cultured human umbilical vein endothelial cells (HUVEC). We found that vasostatin could inhibit the cell viability of HUVEC and induce cell apoptosis through mitochondrial pathways via activation of caspase-3 under oxygen deprivation conditions. Meanwhile, vasostatin also inhibited vascular endothelial growth factor-induced proliferation and tube formation of HUVEC. The possible mechanism of vasostatin-inhibited proliferation of HUVEC could be through down-regulation of endothelial nitric oxide synthase. These findings suggest that vasostatin could regulate endothelial cell function and might be used in anti-angiogenesis treatment.